This page shows the latest Q4 results news and features for those working in and with pharma, biotech and healthcare.
Bluebird is in partnership with BMS for a BCMA-targeting cell therapy – bb2121 or ide-cel – which recently demonstrated positive top-line results in multiple myeloma. ... Despite making headway in Europe, Zynteglo – also called LentiGlobin – is
The guidance “assumes an unfavourable impact from China lasting up to a few months as a result of the recent novel coronavirus…outbreak”, says AZ in its results statement. ... It added that it will “monitor closely the development of the
It hopes to “define next steps for the clinical programme to bring palovarotene to patients as quickly as possible”, according to its annual results statement. ... Rival candidates for FOP are however coming through the pipeline, including
Allergan has topped expectations in what could be its last set of independent results ahead of its merger with AbbVie, due to close later this quarter. ... Meanwhile, AbbVie’s fourth-quarter results showed that other diversification efforts –
time to register on the results period. ... Analysts said the results bode well for AbbVie’s plans to accommodate the slowdown in Humira, even ahead of the Allergan merger going through, expected sometime this quarter.
BMS share price up by 3% on the back of results.
More from news
Approximately 11 fully matching, plus 27 partially matching documents found.
We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...